Myriad Mulls Split of Molecular Dx, Pharma Businesses
Myriad Genetics said this week that it will conduct a review of its business and consider the possibility of splitting up its molecular diagnostic business and pharmaceutical business as independent operating entities.
The Salt Lake City-based firm noted the possibility of the split or other corporate restructuring in a statement announcing its fourth-quarter and fiscal-year 2008 results.
GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
NPR reports that with medical data being big business, some companies want to get patients involved.
The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.
This webinar will address a range of methods for optimizing small RNA library preparation.
With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.
This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.